Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase NA 2Phase EARLY_PHASE1 2Phase 1 2

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 3Stage I Mixed Cell Type Kidney Wilms Tumor 1

Interventions

Sunitinib 20Nivolumab 16cabozantinib 12Sorafenib 12pembrolizumab 11pazopanib 9Ipilimumab 9Interferon-alpha 9belzutifan 8Everolimus 8lenvatinib 7Bevacizumab 7aldesleukin 6Magnetic Resonance Spectroscopy 6Axitinib 6atezolizumab 5Interferon alpha-2 4temsirolimus 3Specimen Handling 3Radiosurgery 3Nephrectomy 3Interleukin-2 3tivozanib 2durvalumab 2avelumab 2Saline Solution 2G250 monoclonal antibody 2Fluorouracil 2Chemotherapy, Adjuvant 2CTLA-4 Antigen 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Renal Cell × Nephrectomy × Clear all
NCT03055013 2026-06-03

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

National Cancer Institute (NCI)

Phase 3 Active not recruiting
819 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
298 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00930033 2025-09-05

CARMENA

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
452 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡